High Mobility Group Box 1 Contributes to the Pathogenesis of Experimental Pulmonary Hypertension via Activation of Toll-like Receptor 4

Survival rates for patients with pulmonary hypertension (PH) remain low, and our understanding of the mechanisms involved are incomplete. Here we show in a mouse model of chronic hypoxia (CH)-induced PH that the nuclear protein and damage-associate molecular pattern molecule (DAMP) high mobility group box 1 (HMGB1) contributes to PH via a Toll-like receptor 4 (TLR4)-dependent mechanism. We demonstrate extranuclear HMGB1 in pulmonary vascular lesions and increased serum HMGB1 in patients with idiopathic pulmonary arterial hypertension. The increase in circulating HMGB1 correlated with mean pulmonary artery pressure. In mice, we similarly detected the translocation and release of HMGB1 after exposure to CH. HMGB1-neutralizing antibody attenuated the development of CH-induced PH, as assessed by measurement of right ventricular systolic pressure, right ventricular hypertrophy, pulmonary vascular remodeling and endothelial activation and inflammation. Genetic deletion of the pattern recognition receptor TLR4, but not the receptor for advanced glycation end products, likewise attenuated CH-induced PH. Finally, daily treatment of mice with recombinant human HMGB1 exacerbated CH-induced PH in wild-type (WT) but not Tlr4−/− mice. These data demonstrate that HMGB1-mediated activation of TLR4 promotes experimental PH and identify HMGB1 and/or TLR4 as potential therapeutic targets for the treatment of PH.

[1]  T. Kanda,et al.  Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: Possible implication for TLR4-signalling and chronic immune activation , 2013, Innate immunity.

[2]  L. Yazmalar,et al.  Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life , 2013, Rheumatology International.

[3]  V. Heinemann,et al.  Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy , 2013, Tumor Biology.

[4]  T. Billiar,et al.  High Mobility Group Box 1 Inhibits Human Pulmonary Artery Endothelial Cell Migration via a Toll-like Receptor 4- and Interferon Response Factor 3-dependent Mechanism(s)* , 2012, The Journal of Biological Chemistry.

[5]  M. Guzmán,et al.  Elevated serum levels of high mobility group box 1 (HMGB1) protein in dengue-infected patients are associated with disease symptoms and secondary infection. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  Si-young Song,et al.  Serum high mobility group box‐1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma , 2012, Cancer science.

[7]  H. Naruse,et al.  Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. , 2012, Atherosclerosis.

[8]  V. Gangji,et al.  Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome , 2012, Scandinavian journal of rheumatology.

[9]  K. Tracey,et al.  Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis , 2012, Arthritis Research & Therapy.

[10]  S. Erzurum,et al.  Complement C3 Deficiency Attenuates Chronic Hypoxia-Induced Pulmonary Hypertension in Mice , 2011, PloS one.

[11]  Xin J. Zhou,et al.  Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. , 2011, Kidney international.

[12]  J. A. Nogueira-Machado,et al.  HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation , 2011, Expert opinion on therapeutic targets.

[13]  I. Maruyama,et al.  The Role Of High Mobility Group Box1 In Monocrotaline-Induced Pulmonary Hypertension In Rats , 2011, ATS 2011.

[14]  S. Akira,et al.  Pathogen Recognition by the Innate Immune System , 2011, International reviews of immunology.

[15]  M. Bianchi,et al.  TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells , 2010, The EMBO journal.

[16]  S. Akira,et al.  A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release , 2010, Proceedings of the National Academy of Sciences.

[17]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[18]  E. Aronica,et al.  Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.

[19]  M. Andrassy,et al.  The Role of HMGB1/RAGE in Inflammatory Cardiomyopathy , 2010, Seminars in thrombosis and hemostasis.

[20]  Carsten Ehrhardt,et al.  The Receptor for Advanced Glycation End Products (RAGE) and the Lung , 2010, Journal of biomedicine & biotechnology.

[21]  D. Hackam,et al.  Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis. , 2010, Gastroenterology.

[22]  R. Rieben,et al.  TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. , 2009, Molecular immunology.

[23]  M. Maitland,et al.  Inflammation, growth factors, and pulmonary vascular remodeling. , 2009, Journal of the American College of Cardiology.

[24]  P. Thistlethwaite,et al.  Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[25]  E. Mark,et al.  Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.

[26]  S. Eddahibi,et al.  Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice , 2009, Respiratory research.

[27]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[28]  M. Wilkins,et al.  Emerging concepts and translational priorities in pulmonary arterial hypertension. , 2008, Circulation.

[29]  Merlin C. Thomas,et al.  Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. , 2008, American journal of physiology. Endocrinology and metabolism.

[30]  T. Billiar,et al.  HMGB1: Endogenous Danger Signaling , 2008, Molecular medicine.

[31]  M. Cinelli,et al.  Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension , 2007, Annals of the rheumatic diseases.

[32]  M. Rabinovitch Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.

[33]  K. Tracey,et al.  Systemic inflammation and remote organ injury following trauma require HMGB1. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  L. Tavazzi,et al.  A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. , 2007, American heart journal.

[35]  R. Tuder,et al.  Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.

[36]  M. Rabinovitch Pathobiology of pulmonary hypertension. , 2007, Annual review of pathology.

[37]  M. Bianchi DAMPs, PAMPs and alarmins: all we need to know about danger , 2007, Journal of leukocyte biology.

[38]  E. Abraham,et al.  High mobility group box 1 protein interacts with multiple Toll-like receptors. , 2006, American journal of physiology. Cell physiology.

[39]  R. Folz,et al.  Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). , 2006, American journal of physiology. Lung cellular and molecular physiology.

[40]  P. Kubes,et al.  Platelets express functional Toll-like receptor-4. , 2005, Blood.

[41]  K. Tracey,et al.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.

[42]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[43]  E. Schleicher,et al.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.

[44]  E. Abraham,et al.  Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein* , 2004, Journal of Biological Chemistry.

[45]  W. Seeger,et al.  Clinical classification of pulmonary hypertension. , 2001, Clinics in chest medicine.

[46]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Lotze,et al.  Dealing with death: HMGB1 as a novel target for cancer therapy. , 2003, Current opinion in investigational drugs.

[48]  G. Längst,et al.  The DNA chaperone HMGB1 facilitates ACF/CHRAC‐dependent nucleosome sliding , 2002, The EMBO journal.

[49]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[50]  T. Minamino,et al.  Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  F. Katsuoka,et al.  Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. , 1997, Biochemical and biophysical research communications.

[52]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[53]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[54]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[55]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[56]  B. Munt,et al.  Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. , 1992, The Journal of rheumatology.

[57]  D. Friedman,et al.  Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease. , 1992, Annals of the rheumatic diseases.